Research and Clinical Trials

The patients and team at the Myeloma Center are involved in a number of clinical trials to help advance the field so that the goal of finding a cure for myeloma can be achieved. The clinical trial protocols available are a mixture of investigator-initiated trials (i.e. Cornell-specific), pharmaceutical studies, and myeloma collaborative studies (i.e. multi-institutional). Clinical trials are often referred to as Phase 1 (the drug is being used in people for the first time, thus different doses and schedules of dosing are being tested), Phase 2 (the drug dose has been defined, but efficacy needs to be established), or Phase 3 (the new drug is being compared to the older established standard of care to see if it is, in fact, better).

Currently active clinical trials are divided into those for upfront (1st line therapy) and those for patients with relapsed or progressive myeloma that is not responding to standard therapies.

Selected Upfront Trials available at the Myeloma Center

  1. A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone Therapy for Subjects with Newly Diagnosed Multiple Myeloma.
  2. A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients with Symptomatic Multiple Myeloma
  3. A Phase 3, Randomized Open Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
  4. A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
  5. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma

Selected Available Trials for Relapsed Myeloma

  1. Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma.
  2. A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma
  3. A Phase 1 / 2 Study, Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma
  4. A Phase 3, Randomized, Double Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone In Adult Patients With Relapsed And/Or Refractory Multiple MyelomaM.
  5. A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
  6. An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma

There are more trials available than those listed above, which you can access by clicking the link below. If interested in a clinical trial, please contact your Myeloma Center physician to help find the right one for you.